Goldman Sachs Group Analysts Give Bayer (FRA:BAYN) a €77.00 Price Target

Goldman Sachs Group set a €77.00 ($89.53) price target on Bayer (FRA:BAYN) in a research report released on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other research firms have also recently issued reports on BAYN. Barclays set a €85.00 ($98.84) price objective on Bayer and gave the company a buy rating in a research report on Tuesday, July 30th. Credit Suisse Group set a €70.00 ($81.40) price objective on Bayer and gave the company a buy rating in a research report on Wednesday, July 31st. UBS Group set a €110.00 ($127.91) price objective on Bayer and gave the company a buy rating in a research report on Monday, August 5th. Nord/LB set a €56.00 ($65.12) price objective on Bayer and gave the company a neutral rating in a research report on Tuesday, July 30th. Finally, Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the company a buy rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of €80.57 ($93.68).

BAYN opened at €62.98 ($73.23) on Monday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98). The company has a 50 day simple moving average of €59.42.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: What is the Quick Ratio?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.